. Author manuscript; available in PMC: 2024 Dec 1.

Published in final edited form as: Toxicology. 2023 Nov 27;500:153684. doi: 10.1016/j.tox.2023.153684

Table 5.

Margin of safety (MOS).

Compound	HED	Parameter	Mean	1^st percentile	99^th percentile	MOS
Thalidomide	In vitro HED¹ 10.06 mg/day	C_max (μg/L)	107.11	50.90	193.97	0.05
	In vitro HED¹ 10.06 mg/day	AUC24 (μg*h/L)	964	478	1725
	Therapeutic dose 50 mg/day	C_max (μg/L)	527.59	250.92	981.14
	Therapeutic dose 50 mg/day	AUC24 (μg*h/L)	4767	2302	8934
Carbamazepine	In vitro HED¹ 98.1 mg/day	C_max (μg/L)	1925	1070	3328	0.15
	In vitro HED¹ 98.1 mg/day	AUC24 (μg*h/L)	41817	22545	73209
	Therapeutic dose 200 mg/day	C_max (μg/L)	3889	2148	6859
	Therapeutic dose 200 mg/day	AUC24 (μg*h/L)	84145	45964	150512

Human equivalent doses derived using the PBPK model and assuming the LOAEL concentration of 0.4 μM for thalidomide and 7.8 μM for carbamazepine from the ReproTracker are plasma concentrations.